About: In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates
Creator	Wang, Ning Zhang, Yan Jiang, Jin-Hua Ma, Fang Sun, Chang-Yu Wang, Qing-Duan Wang, Ya-Feng Yang, Xiao-Ang Yin, De-Tao Zheng, Li-Yun Zhou, Yu-Bing
Source	Elsevier; Medline; PMC
abstract	Abstract Hepatitis B virus (HBV) infection causes major public health problems worldwide. The clinical limitation of current antiviral drugs for HBV, such as lamivudine, is the emergence of drug-resistant viral strains during prolonged antiviral therapy. Cepharanthine hydrochloride (CH), a natural alkaloid-derived compound, has been reported to possess potent activity against various viruses. The present study was performed to evaluate the in vitro activity of CH against clinical wild-type and lamivudine-resistant HBV isolates in transiently transfected cells. HBV DNA was extracted from serum samples collected both before lamivudine therapy and at the time of viral breakthrough and was amplified by polymerase chain reaction (PCR). The amplicons were cloned into a novel expression vector, pHY106, which can initiate the intracellular HBV replication cycle after cell transfection. Following transfection of the cloned amplicon into HepG2 cells, a drug susceptibility assay was performed. The level of viral antigen, HBeAg, was determined by enzyme-linked immunosorbent assay (ELISA). Quantitative real-time PCR (Q-PCR) was used for determining the amount of intracellular HBV DNA. Heat stress cognate 70 (Hsc70), a host protein required for HBV replication, was also analyzed by reverse transcription PCR (RT-PCR) to explore the possible antiviral mechanism of CH. The results showed that CH inhibited replication and HBeAg production by either wild-type or lamivudine-resistant HBV clinical isolates in a dose-dependent manner. The Hsc70 mRNA was also downregulated significantly. In conclusion, CH is active against both wild-type and lamivudine-resistant HBV clinical isolates, and its activity may be associated with its inhibition of host Hsc70.
has issue date	2012-05-15(xsd:dateTime)
bibo:doi	10.1016/j.ejphar.2012.02.030
bibo:pmid	22387093
has license	els-covid
sha1sum (hex)	392d6a3aa7466a54c4261b5f43011edbc813b8ef
schema:url	https://doi.org/10.1016/j.ejphar.2012.02.030
resource representing a document's title	In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates
has PubMed Central identifier	PMC7094493
has PubMed identifier	22387093
schema:publication	European Journal of Pharmacology
resource representing a document's body	covid:392d6a3aa7466a54c4261b5f43011edbc813b8ef#body_text
is schema:about of	named entity 'mRNA' named entity 'inhibition' named entity 'cloned' named entity 'cognate' named entity 'downregulated' named entity 'isolates' named entity 'HepG2' named entity 'protein' named entity 'activity' named entity 'MAJOR' named entity 'ANTIVIRAL DRUGS' named entity 'HSC70' named entity 'DRUG' named entity 'ANTIVIRAL THERAPY' named entity 'WILD-TYPE' named entity 'LEVEL' named entity 'REPORTED' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'PUBLIC HEALTH' named entity 'VIRAL ANTIGEN' named entity 'DOSE-DEPENDENT' named entity 'HOST' named entity 'REVERSE TRANSCRIPTION PCR' named entity 'PERFORMED' named entity 'ACTIVITY' named entity 'COLLECTED' named entity 'NOVEL' named entity 'CLINICAL' named entity 'STUDY' named entity 'CLONED' named entity 'ANTIVIRAL' named entity 'HEPATITIS B VIRUS' named entity 'ITS' named entity 'PRODUCTION' named entity 'EVALUATE' named entity 'TRANSFECTION' named entity 'MRNA' covid:arg/392d6a3aa7466a54c4261b5f43011edbc813b8ef named entity 'VIRUSES' named entity 'AMPLICON' named entity 'HEPATITIS B VIRUS' named entity 'CONCLUSION' named entity 'LAMIVUDINE' named entity 'REPLICATION' named entity 'SERUM' named entity 'NATURAL' named entity 'REQUIRED' named entity 'CEPHARANTHINE' named entity 'WILD-TYPE' named entity 'HYDROCHLORIDE' named entity 'CLINICAL' named entity 'LAMIVUDINE' named entity 'IN VITRO ACTIVITY' named entity 'PROLONGED' named entity 'AMPLIFIED' named entity 'ASSOCIATED WITH' named entity 'VARIOUS' named entity 'IN VITRO ACTIVITY' named entity 'HBV' named entity 'FOLLOWING' named entity 'VIRAL' named entity 'INITIATE' named entity 'VIRAL BREAKTHROUGH' named entity 'SAMPLES' named entity 'WORLDWIDE' named entity 'CAUSES' named entity 'RESISTANT' named entity 'EXTRACTED' named entity 'HYDROCHLORIDE' named entity 'REPLICATION CYCLE' named entity 'DERIVED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software